230 biotech companies with about 5,300 employees research and develop new products and processes, particularly in the field of red biotechnology.
The city is unique in Europe for its many independent research institutions working outside of a university context. Nowhere else is such variety to be found in such concentration, and nowhere else is research performed at such levels of excellence. Together, these institutes provide an exceptional platform for innovation, which is aided further by their close ties to partners in the industry. Moreover, the capital’s over 130 hospitals and contract research organizations (CROs) provide excellent opportunities for collaborating on clinical studies.
Every year, 3,000 people graduate from Berlin's universities with degrees in fields related to the life sciences. This, together with the targeted promotion of further education opportunities in the capital region, ensures a good supply of highly qualified specialists and managers for the biotech industry.
„We founded OMEICOS Therapeutics on the base of research results, generated at the Max-Delbrück-Center for Molecular Medicine. Our continuous close collaboration with MDC and other partners in Berlin is of great value for OMEICOS’ success. As pioneers in the field of synthetic omega-3 epoxyeicosanoid analogs, we are developing small molecules for cardiovascular and ophthalmic indications.“
To name but a few examples, successful companies that are located in Berlin are:
- 3B Pharmaceuticals
- JPT Peptide Technologies,
- Omeicos Therapeutics and